# Timberlyne Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/timberlyne-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.timberlyne-tx.com
- Total disclosed funding: $180M
- Latest round: Series A (Jan 9, 2025)
- Investors on record: 7

## About

Based in California, US, and founded in 2024 by Christian Fougner, Timberlyne Therapeutics operates as a clinical-stage biopharmaceutical company developing novel therapies for treating patients with autoimmune diseases. In January 2025, Timberlyne Therapeutics raised USD 180 million in Series A funding co-led by Venrock Healthcare Capital Partners, Bain Capital Life Sciences, and Abingworth, with participation from 3H Health Investment Management (Hong Kong) Limited, Braidwell Lp, Lilly Asia Ventures and Boyu Capital.

The firm’s lead product, CM313, is an IgG1 monoclonal antibody specifically designed to target CD38, a protein highly expressed on plasma cells and various immune cells. CM313 enhances complement-dependent cytotoxicity, allowing it to effectively modulate the immune system and potentially provide rapid and durable responses in treating conditions such as Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. This product is positioned to address significant unmet medical needs in the autoimmune disease market, with plans for further development across multiple autoimmune indications. 

The company intends to use the January 2024 funding to improve CM313, a CD38-targeting antibody, through clinical development for autoimmune diseases.

## Funding rounds

- Series A, Jan 9, 2025, $180M — Abingworth, Lilly Asia Ventures, Boyu Capital, Bain Capital Life Sciences, 3H Health Investment, Venrock Healthcare Capital Partners, Braidwell Lp

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- Bain Capital Life Sciences — Series A
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series A
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series A
- Braidwell Lp — Series A